Privi Speciality Chemicals Credit Rating

Privi Speciality Chemicals Other Announcement

Privi Speciality Chemicals Ltd filed its quarterly shareholding pattern for the period ending 30 September 2026. Shareholding Pattern statements are routine regulatory disclosures with no transaction or business event.

Privi Speciality Chemicals Investor Presentation: Key Takeaways

Q2 FY27 total income Rs 773.16 Cr (+13.9%), EBITDA Rs 212.49 Cr (27.5% margin, +65bps), PAT Rs 117.03 Cr (+24.6%). H1 FY27 PAT +29.1%. Targets Rs 5,000 Cr revenue by FY29-30.

Privi Speciality Chemicals Dividend

Privi Speciality Chemicals declared an interim dividend of Rs 5 per equity share for FY 2026-27 at its 29 October 2026 board meeting. Record date is 04 November 2026 and payment by 25 November 2026.

Privi Speciality Chemicals Q2 FY27 Results: Net Profit ₹117.5 Cr, Up 30.3% YoY

Privi Speciality Chemicals Ltd reported revenue from operations of ₹760.5 Cr (+12.1% YoY) and net profit of ₹117.5 Cr (+30.3% YoY) for Q2 FY27.

Key figure

Net profit ₹117.5 Cr · +30.3% YoY

Privi Speciality Chemicals Acquisition

Privi Speciality Chemicals' NCLT-convened equity shareholder meeting approved the Scheme of Amalgamation of Privi Fine Sciences and Privi Biotechnologies into the company. The special resolution passed with requisite majority, subject to scrutinizer report.

Privi Speciality Chemicals Board Meeting Date

Privi Speciality Chemicals intimated its board meeting is scheduled for October 29, 2026, to consider Q1/H1 results and an interim dividend. Items are proposed only and not yet decided.

Singer India Credit Rating

Singer India's Rs.45 Crore bank facilities were re-rated by CRISIL. Long-term stayed BBB-/Stable while the short-term rating was upgraded to Crisil A3+.

Bondada Engineering Credit Rating

CRISIL upgraded credit ratings for five subsidiaries of Bondada Engineering to A/Stable or A-/Stable. The upgrade reflects strong financials and supports the group's lender credibility.

20 Microns Credit Rating

CRISIL reaffirmed 20 Microns' bank loan ratings at A/Stable and A1 on ₹117 crore facilities. Ratings remain unchanged from prior assessment.

Epigral Credit Rating

CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.

Mankind Pharma Credit Rating

CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.

Lloyds Metals & Energy Credit Rating

Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.